{"id":3582,"date":"2025-03-27T11:10:43","date_gmt":"2025-03-27T10:10:43","guid":{"rendered":"https:\/\/invivo.partners\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/"},"modified":"2025-03-27T12:14:37","modified_gmt":"2025-03-27T11:14:37","slug":"were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii","status":"publish","type":"post","link":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/","title":{"rendered":"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III."},"content":{"rendered":"

Aquest grup excepcional d\u2019experts en biologia sint\u00e8tica, ter\u00e0pies d\u2019ARN, ter\u00e0pies avan\u00e7ades i intel\u00b7lig\u00e8ncia artificial proporcionar\u00e0 una orientaci\u00f3 valuosa mentre continuem invertint en el futur de la innovaci\u00f3 biotecnol\u00f2gica.<\/strong><\/p>\n

 <\/p>\n

Veure PR<\/a>.<\/p>\n

\"\"Luis Serrano, Ph.D. <\/strong><\/span>Director, CRG (Centre de Regulaci\u00f3 Gen\u00f2mica).<\/span><\/p>\n

El Dr. Luis Serrano va obtenir el seu doctorat en Biologia Cel\u00b7lular al CBM (Madrid, Espanya) i posteriorment va dur a terme investigacions postdoctorals sobre el plegament de prote\u00efnes al MRC (Regne Unit) sota la supervisi\u00f3 del Prof. A.R. Fehrst. L\u2019any 1993, es va incorporar a l\u2019EMBL (Heidelberg, Alemanya) com a Cap de Grup, centrant-se en el plegament i el disseny de prote\u00efnes. Una d\u00e8cada m\u00e9s tard, va ser nomenat Cap del programa de Biologia Estructural i Computacional a l\u2019EMBL, on va impulsar la recerca en Biologia de Sistemes i Biologia Sint\u00e8tica.<\/span><\/p>\n

El 2006, el Dr. Serrano va tornar a Espanya per establir un programa de recerca en Biologia de Sistemes, exercint com a vicedirector abans de ser nomenat Director del CRG al juliol del 2011. <\/span><\/p>\n

La seva recerca actual se centra en la Biologia Sint\u00e8tica, especialment en l\u2019enginyeria i el disseny de sistemes biol\u00f2gics. Reconeixut com un l\u00edder en el seu camp, \u00e9s membre d\u2019EMBO i RACEFyN i ha rebut diversos premis internacionals prestigiosos, incloent-hi el Marie Curie Excellence Award, tres ERC Advanced Grants i guardons com el Premi Ciutat de Barcelona, el Premi Fundaci\u00f3 Cobos i el Premi Jaume I en noves tecnologies. <\/span><\/p>\n

A m\u00e9s, ha estat coordinador de m\u00faltiples projectes de recerca finan\u00e7ats per la UE i ha cofundat sis empreses emergents.<\/span><\/p>\n

\"\"Bego\u00f1a Carre\u00f1o, Ph.D. <\/strong><\/span>Directora de Desenvolupament de Negoci a Aspeya.<\/span><\/p>\n

La Dra. Bego\u00f1a Carre\u00f1o \u00e9s actualment la Directora de Desenvolupament de Negoci a Aspeya (anteriorment coneguda com a Vectura Fertin Pharma) a Su\u00efssa. Abans d’aix\u00f2, va passar 18 anys a Novartis Pharma AG en el grup de Desenvolupament de Negoci i Llic\u00e8ncies (\u00abBD&L\u00bb), sent el seu \u00faltim c\u00e0rrec el de Directora Mundial de BD&L en la franqu\u00edcia d’Oftalmologia, amb base a Basilea, Su\u00efssa.<\/span><\/p>\n

La Dra. Carre\u00f1o compta amb m\u00e9s de 20 anys d’experi\u00e8ncia en desenvolupament farmac\u00e8utic. \u00c9s una professional experta i din\u00e0mica en BD&L, havent liderat aquesta \u00e0rea a Novartis en cinc franqu\u00edcies terap\u00e8utiques diferents durant els \u00faltims 15 anys, incloent-hi cardiovascular i metabolisme, respiratori, artritis, ossos i malalties musculoesquel\u00e8tiques.<\/span><\/p>\n

T\u00e9 una \u00e0mplia experi\u00e8ncia en acords de llic\u00e8ncies, fusions i adquisicions (M&A), aix\u00ed com en el desenvolupament de col\u00b7laboracions en entorns multidisciplinaris, multiculturals i matricials a nivell global, regional i nacional. Abans d’incorporar-se a Novartis, va ser la Responsable de Projectes Farmac\u00e8utics Externs a Almirall (Barcelona, Espanya).<\/span><\/p>\n

Actualment, \u00e9s membre no executiva del consell d’administraci\u00f3 de ProQR, una companyia p\u00fablica especialitzada en edici\u00f3 d’ARN, i forma part del Consell Assessor de Negoci de l\u2019IRB a Barcelona.<\/span><\/p>\n

La Dra. Carre\u00f1o \u00e9s doctora en Administraci\u00f3 de F\u00e0rmacs per la London School of Pharmacy (Regne Unit) i llicenciada en Bioqu\u00edmica per la Keele University (Regne Unit).<\/span><\/p>\n

\"\"Josep Maria (Pep) Martorell, Ph.D. <\/strong><\/span>Director Associat, Barcelona Supercomputing Center (BSC).<\/span><\/p>\n

El Dr. Josep Maria Martorell t\u00e9 una \u00e0mplia experi\u00e8ncia en gesti\u00f3 acad\u00e8mica i cient\u00edfica, especialment en la intersecci\u00f3 entre la recerca i les pol\u00edtiques governamentals. \u00c9s llicenciat en F\u00edsica per la Universitat de Barcelona (UB) i doctor en Inform\u00e0tica per la Universitat Ramon Llull (URL).<\/span><\/p>\n

Ha ocupat c\u00e0rrecs destacats, incloent-hi cinc anys com a Director General de Recerca del Govern de Catalunya, on va tenir un paper clau en la configuraci\u00f3 de les pol\u00edtiques de recerca regionals. Des de l\u2019abril de 2016, exerceix com a Director Associat del Barcelona Supercomputing Center (BSC), contribuint als aven\u00e7os cient\u00edfics estrat\u00e8gics.<\/span><\/p>\n

El Dr. Martorell tamb\u00e9 ha participat en programes de formaci\u00f3 executiva a ESADE (VV-2004) i IESE (PDD-2009). A m\u00e9s de la seva traject\u00f2ria acad\u00e8mica i governamental, \u00e9s un Business Angel actiu i mentor de diverses start-ups tecnol\u00f2giques a Barcelona.<\/span><\/p>\n

\"\"Theresa Heggie. <\/strong><\/span>Executiva Biofarmac\u00e8utica i Membre de Consells d\u2019Administraci\u00f3.<\/span><\/p>\n

Theresa<\/span> Heggie \u00e9s una executiva de gran prestigi en les ind\u00fastries biotecnol\u00f2gica i farmac\u00e8utica, amb una \u00e0mplia experi\u00e8ncia en lideratge d’estrat\u00e8gies comercials globals, operacions, desenvolupament de negoci i acc\u00e9s al mercat.<\/span><\/p>\n

Es va unir a Freeline com a CEO el juny de 2020, dirigint el desenvolupament cl\u00ednic de la companyia des de la seva seu al nord de Londres. Pr\u00e8viament, va ser Vicepresidenta S\u00e8nior i Responsable de CEMEA a Alnylam Pharmaceuticals, una empresa biotecnol\u00f2gica pionera en ter\u00e0pies basades en interfer\u00e8ncia d\u2019ARN (RNAi). Tamb\u00e9 ha ocupat c\u00e0rrecs de lideratge com a Directora d\u2019Estrat\u00e8gia i M\u00e0rqueting a Bupa i Vicepresidenta S\u00e8nior d\u2019Operacions Comercials Globals a Shire Human Genetic Therapies, on tamb\u00e9 va ser CEO de Jerini despr\u00e9s de la seva adquisici\u00f3 per part de Shire. Al principi de la seva carrera, va ocupar posicions de lideratge a Baxter i Janssen.<\/span><\/p>\n

Actualment, la Sra. Heggie \u00e9s membre dels consells d\u2019administraci\u00f3 de BioCryst Pharmaceuticals i ProQR Therapeutics. T\u00e9 una llicenciatura en Ci\u00e8ncies per la Cornell University.<\/span><\/p>\n

\"\"Dr. Timothy Lu. <\/strong><\/span>Cofundador i Director Executiu, Senti Bio.<\/span><\/p>\n

El Dr. Timothy Lu \u00e9s un referent en biologia sint\u00e8tica i innovaci\u00f3 biofarmac\u00e8utica. Des que va cofundar Senti Bio el 2016, n\u2019ha estat el CEO, liderant el desenvolupament de ter\u00e0pies g\u00e8niques i cel\u00b7lulars avan\u00e7ades.<\/span><\/p>\n

Es va incorporar al MIT com a professor als departaments d\u2019Enginyeria Biol\u00f2gica i Enginyeria El\u00e8ctrica i Ci\u00e8ncies de la Computaci\u00f3 el 2010. Durant la seva traject\u00f2ria acad\u00e8mica, el Dr. Lu va impulsar investigacions pioneres en el disseny de circuits gen\u00e8tics intel\u00b7ligents per a aplicacions terap\u00e8utiques. Ha cofundat i assessorat m\u00faltiples empreses biotecnol\u00f2giques, entre elles Senti, BiomX, Corvium, Eligo Bioscience, Engine Biosciences, Synlogic i Tango Therapeutics.<\/span><\/p>\n

El Dr. Lu va obtenir el seu t\u00edtol de doctor en Medicina per la Harvard Medical School i el seu doctorat en Enginyeria El\u00e8ctrica i Biom\u00e8dica pel MIT a trav\u00e9s del programa de Ci\u00e8ncies i Tecnologia de la Salut Harvard-MIT. <\/span><\/p>\n

El seu treball innovador ha estat reconegut amb nombrosos premis, incloent-hi el NIH New Innovator Award, el US Presidential Early Career Award for Scientists and Engineers, el MIT Technology Review\u2019s TR35, i els Premis Young Investigator de la Marina i l\u2019Ex\u00e8rcit dels EUA.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

Aquest grup excepcional d\u2019experts en biologia sint\u00e8tica, ter\u00e0pies d\u2019ARN, ter\u00e0pies avan\u00e7ades i intel\u00b7lig\u00e8ncia artificial proporcionar\u00e0 una orientaci\u00f3 valuosa mentre continuem invertint en el futur de la innovaci\u00f3 biotecnol\u00f2gica.   Veure PR. Luis Serrano, Ph.D. Director, CRG (Centre de Regulaci\u00f3 Gen\u00f2mica). El Dr. Luis Serrano va obtenir el seu doctorat en Biologia Cel\u00b7lular al CBM (Madrid,<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[516],"tags":[],"class_list":["post-3582","post","type-post","status-publish","format-standard","hentry","category-noticias-ca"],"acf":[],"yoast_head":"\nEstem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III. - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III. - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Aquest grup excepcional d\u2019experts en biologia sint\u00e8tica, ter\u00e0pies d\u2019ARN, ter\u00e0pies avan\u00e7ades i intel\u00b7lig\u00e8ncia artificial proporcionar\u00e0 una orientaci\u00f3 valuosa mentre continuem invertint en el futur de la innovaci\u00f3 biotecnol\u00f2gica.   Veure PR. Luis Serrano, Ph.D. Director, CRG (Centre de Regulaci\u00f3 Gen\u00f2mica). El Dr. Luis Serrano va obtenir el seu doctorat en Biologia Cel\u00b7lular al CBM (Madrid,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-27T10:10:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-27T11:14:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/invivo.partners\/wp-content\/uploads\/2025\/03\/luis_serrano_web-150x150.jpg\" \/>\n<meta name=\"author\" content=\"Bego\u00f1a Aguirre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bego\u00f1a Aguirre\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/\"},\"author\":{\"name\":\"Bego\u00f1a Aguirre\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\"},\"headline\":\"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III.\",\"datePublished\":\"2025-03-27T10:10:43+00:00\",\"dateModified\":\"2025-03-27T11:14:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/\"},\"wordCount\":1135,\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/\",\"url\":\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/\",\"name\":\"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III. - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2025-03-27T10:10:43+00:00\",\"dateModified\":\"2025-03-27T11:14:37+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\",\"name\":\"Bego\u00f1a Aguirre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"caption\":\"Bego\u00f1a Aguirre\"},\"url\":\"https:\/\/invivo.partners\/ca\/author\/bego\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III. - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/","og_locale":"ca_ES","og_type":"article","og_title":"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III. - Invivo Partners","og_description":"Aquest grup excepcional d\u2019experts en biologia sint\u00e8tica, ter\u00e0pies d\u2019ARN, ter\u00e0pies avan\u00e7ades i intel\u00b7lig\u00e8ncia artificial proporcionar\u00e0 una orientaci\u00f3 valuosa mentre continuem invertint en el futur de la innovaci\u00f3 biotecnol\u00f2gica.   Veure PR. Luis Serrano, Ph.D. Director, CRG (Centre de Regulaci\u00f3 Gen\u00f2mica). El Dr. Luis Serrano va obtenir el seu doctorat en Biologia Cel\u00b7lular al CBM (Madrid,","og_url":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/","og_site_name":"Invivo Partners","article_published_time":"2025-03-27T10:10:43+00:00","article_modified_time":"2025-03-27T11:14:37+00:00","og_image":[{"url":"https:\/\/invivo.partners\/wp-content\/uploads\/2025\/03\/luis_serrano_web-150x150.jpg"}],"author":"Bego\u00f1a Aguirre","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Bego\u00f1a Aguirre","Temps estimat de lectura":"6 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/#article","isPartOf":{"@id":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/"},"author":{"name":"Bego\u00f1a Aguirre","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee"},"headline":"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III.","datePublished":"2025-03-27T10:10:43+00:00","dateModified":"2025-03-27T11:14:37+00:00","mainEntityOfPage":{"@id":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/"},"wordCount":1135,"publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"articleSection":["Noticias"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/","url":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/","name":"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III. - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2025-03-27T10:10:43+00:00","dateModified":"2025-03-27T11:14:37+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/2025\/03\/27\/were-delighted-to-welcome-our-newly-formed-scientific-advisory-board-sab-for-invivo-ventures-iii\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"Estem encantats de donar la benvinguda al nostre recentment format Consell Assessor Cient\u00edfic (CAC) per a Invivo Ventures III."}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee","name":"Bego\u00f1a Aguirre","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","caption":"Bego\u00f1a Aguirre"},"url":"https:\/\/invivo.partners\/ca\/author\/bego\/"}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/3582","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/comments?post=3582"}],"version-history":[{"count":13,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/3582\/revisions"}],"predecessor-version":[{"id":3626,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/3582\/revisions\/3626"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=3582"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/categories?post=3582"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tags?post=3582"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}